Two stories dominated Alzheimer’s news this year: The FDA’s approval of Leqembi, the first drug to slow progression of the disease, and a surprising study…
A five-year, £5 million initiative has just been launched to investigate the feasibility of using new blood tests in the diagnosis of Alzheimer’s disease. Alzheimer’s…
Higher amounts of visceral abdominal fat in midlife are linked to the development of Alzheimer’s disease, according to research being presented next week at the…
Alzheimer’s disease (AD), the most prevalent neurodegenerative disease globally, poses a significant threat to human health. Most AD patients are diagnosed after the age of…
Scientists at The University of Texas at Dallas Center for Vital Longevity (CVL) have published new evidence that shows changes in brain network patterns that…
The use of gantenerumab leads to lower amyloid plaque burden at 116 weeks, but is not associated with slower clinical decline among patients with early…
A rare but potent genetic mutation that alters a protein in the brain’s immune cells, known as microglia, can give people as much as a…
Alzheimer’s disease is feared by many―and for good reason. The brain disorder slowly destroys memory along with a person’s ability to reason, speak, carry out…
Cambridge scientists have grown small blood vessel-like models in the lab and used them to show how damage to the scaffolding that supports these vessels…
With the rise of new drugs that can target the amyloid-beta plaques in the brain that are an early sign of Alzheimer’s disease, new ways…